Factors associated with long-term efficacy of lubiprostone for chronic constipation

The prevalence of chronic constipation in Japan is increasing, and is presently almost 1 in 5 people. Because constipation is common, especially in older patients, to avoid adverse events and poly­pharmacy, simple treatments at low doses are generally desired. Although the chloride channel activator...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Clinical Biochemistry and Nutrition 2023, Vol.73(1), pp.91-96
Main Authors: Morise, Takashi, Fukuzawa, Masakatsu, Sugimoto, Mitsushige, Nagata, Naoyoshi, Kono, Shin, Yamauchi, Yoshiya, Sugimoto, Akihiko, Uchida, Kumiko, Koyama, Yohei, Madarame, Akira, Yamaguchi, Hayato, Matsumoto, Taisuke, Kagawa, Yasuyuki, Kawai, Takashi, Itoi, Takao
Format: Article
Language:English
Subjects:
Adverse events
Chloride ions
chronic disease
Constipation
Diarrhea
drug therapy
Effectiveness
Ion channels
lubiprostone
Multivariate analysis
Original
Patients
starting dose
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prevalence of chronic constipation in Japan is increasing, and is presently almost 1 in 5 people. Because constipation is common, especially in older patients, to avoid adverse events and poly­pharmacy, simple treatments at low doses are generally desired. Although the chloride channel activator lubiprostone is candidate drug that may solve these problems, factors associated with the long-term efficacy of lubiprostone monotherapy for chronic constipation in treatment-naive patients remain unclear. We here retrospectively investigated the clinical characteristics and factors of patients who achieved long-term constipation improvement with lubiprostone monotherapy. Seventy-four patients with chronic constipation treated with lubiprostone monotherapy (24 or 48 ‍μg/day) from January 2017 to August 2018 were reviewed. Patient characteristics and clinical time-courses were compared between those who sustained improvement for 6 months, and ‍those who became refractory to treatment. In 54 patients (76.1%), constipation improved by lubiprostone administration for 6 months. On multivariate analysis, a significant clinical factor ‍associated with sustained improvement was a starting lubiprostone dose of 24 ‍μg/day (odds ratio: 5.791; 95% confidence interval: 1.032–32.498; p = 0.046). A starting lubiprostone dose of 24 ‍μg/day has efficacy to improve chronic constipation and to prevent adverse events of nausea and diarrhea in Japanese patients.
ISSN:0912-0009
1880-5086
DOI:10.3164/jcbn.22-24